Arcus Biosciences (RCUS) to Release Quarterly Earnings on Thursday

Arcus Biosciences (NYSE:RCUS) is scheduled to be issuing its quarterly earnings data after the market closes on Thursday, August 8th. Analysts expect the company to announce earnings of ($1.02) per share for the quarter. Parties interested in registering for the company’s conference call can do so using this link.

Arcus Biosciences (NYSE:RCUS) last announced its earnings results on Wednesday, May 8th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.97) by $0.92. The company had revenue of $145.00 million for the quarter, compared to the consensus estimate of $28.77 million. Arcus Biosciences had a negative net margin of 97.47% and a negative return on equity of 40.98%. The company’s revenue was up 480.0% on a year-over-year basis. During the same period in the previous year, the business earned ($1.09) EPS. On average, analysts expect Arcus Biosciences to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Arcus Biosciences Stock Up 5.0 %

Shares of Arcus Biosciences stock opened at $14.47 on Wednesday. The stock has a market cap of $1.32 billion, a PE ratio of -4.65 and a beta of 0.90. Arcus Biosciences has a 12 month low of $12.95 and a 12 month high of $25.47. The business has a fifty day simple moving average of $15.34 and a 200-day simple moving average of $16.27.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. Wedbush reaffirmed an “outperform” rating and set a $30.00 target price on shares of Arcus Biosciences in a research note on Thursday, May 9th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arcus Biosciences in a research note on Friday, July 5th. Citigroup lifted their target price on shares of Arcus Biosciences from $36.00 to $38.00 and gave the company a “buy” rating in a research note on Monday, June 3rd. Truist Financial dropped their price target on shares of Arcus Biosciences from $50.00 to $44.00 and set a “buy” rating on the stock in a research note on Monday, June 24th. Finally, Barclays reduced their price objective on Arcus Biosciences from $35.00 to $25.00 and set an “overweight” rating for the company in a research report on Monday, July 8th. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $38.11.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.